He joins the US biotech from private investment firm Colchester Healthcare Investments" />

Please login to the form below

Not currently logged in
Email:
Password:

Ischemix names David DeWahl as CEO

He joins the US biotech from private investment firm Colchester Healthcare Investments

David DeWahl has been appointed president and CEO of US biotech Ischemix.

He joins after stepping down from his role as president of private investment firm Colchester Healthcare Investments.

He has also previously served as VP corporate development at Helix Therapeutics and managing director at Life Science Group – a company he co-founded.

Prior to that, DeWahl was an investment banker with a focus on healthcare the life sciences.

“His background in building life sciences companies and his experience in developing corporate collaborations in the industry and in raising capital will substantially strengthen Ischemix as we continue the clinical development of our drug candidates,” said Dr Reinier Beeuwkes, chairman of the board and chief scientific officer at Ischemix.

These candidates include the company's lead compound CMX-2043, which is being developed to protect against heart and kidney damage due to the interruption of blood flow.

The investigational drug has recently demonstrated positive benefits in phase IIa trials, and further development is expected this year.

11th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics